Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.

ABSTRACT: Dengue virus (DENV) is responsible for approximately 100 million cases of dengue fever annually, including severe forms such as hemorrhagic dengue and dengue shock syndrome. Despite intensive vaccine research and development spanning several decades, a universally accepted and approved vaccine against dengue fever has not yet been developed. The major challenge associated with the development of such a vaccine is that it should induce simultaneous and equal protection against the four DENV serotypes, because past infection with one serotype may greatly increase the severity of secondary infection with a distinct serotype, a phenomenon known as antibody-dependent enhancement (ADE). Using a lentiviral vector platform that is particularly suitable for the induction of cellular immune response

SUBMITTER: Nemirov K 

PROVIDER: S-EPMC10466046 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature